CVS Says Lack Of New Drug Launches Is One Reason For Earnings Decline
Executive Summary
The slowdown in new drug approvals is among the factors contributing to a downturn in CVS' earnings, CEO Tom Ryan told a conference call Oct. 30
You may also be interested in...
Mail Order Poised To Overtake Independents As Number Two Rx Outlet – IMS
Mail-order drug delivery is poised to overtake independent pharmacies as the second largest distribution channel for prescription drugs, IMS VP-Industry Relations Doug Long told the recent Pharmaceutical Care Management Association meeting in Henderson, Nev
Mail Order Poised To Overtake Independents As Number Two Rx Outlet – IMS
Mail-order drug delivery is poised to overtake independent pharmacies as the second largest distribution channel for prescription drugs, IMS VP-Industry Relations Doug Long told the recent Pharmaceutical Care Management Association meeting in Henderson, Nev
U.S. Rx Trends Showing Impact Of Fewer Drug Approvals, IMS Data Suggest
New prescription growth rates in the U.S. appear to reflect a drop-off in the number of new drugs clearing FDA, IMS VP-Industry Relations Doug Long told the Pharmaceutical Care Management Association annual meeting Oct. 14 in Henderson, Nev.